397 related articles for article (PubMed ID: 24608196)
1. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.
Hesketh PJ; Rossi G; Rizzi G; Palmas M; Alyasova A; Bondarenko I; Lisyanskaya A; Gralla RJ
Ann Oncol; 2014 Jul; 25(7):1340-1346. PubMed ID: 24608196
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.
Aapro M; Rugo H; Rossi G; Rizzi G; Borroni ME; Bondarenko I; Sarosiek T; Oprean C; Cardona-Huerta S; Lorusso V; Karthaus M; Schwartzberg L; Grunberg S
Ann Oncol; 2014 Jul; 25(7):1328-1333. PubMed ID: 24603643
[TBL] [Abstract][Full Text] [Related]
3. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.
Gralla RJ; Bosnjak SM; Hontsa A; Balser C; Rizzi G; Rossi G; Borroni ME; Jordan K
Ann Oncol; 2014 Jul; 25(7):1333-1339. PubMed ID: 24631949
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
Zhang L; Lu S; Feng J; Dechaphunkul A; Chang J; Wang D; Chessari S; Lanzarotti C; Jordan K; Aapro M
Ann Oncol; 2018 Feb; 29(2):452-458. PubMed ID: 29092012
[TBL] [Abstract][Full Text] [Related]
5. NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.
Aapro M; Karthaus M; Schwartzberg L; Bondarenko I; Sarosiek T; Oprean C; Cardona-Huerta S; Hansen V; Rossi G; Rizzi G; Borroni ME; Rugo H
Support Care Cancer; 2017 Apr; 25(4):1127-1135. PubMed ID: 27885469
[TBL] [Abstract][Full Text] [Related]
6. Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis.
Navari RM; Binder G; Bonizzoni E; Clark-Snow R; Olivari S; Roeland EJ
Future Oncol; 2021 Aug; 17(23):3027-3035. PubMed ID: 33878896
[TBL] [Abstract][Full Text] [Related]
7. Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting.
Shirley M
Drugs; 2021 Jul; 81(11):1331-1342. PubMed ID: 34292534
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials.
Rugo HS; Rossi G; Rizzi G; Aapro M
Breast; 2017 Jun; 33():76-82. PubMed ID: 28285236
[TBL] [Abstract][Full Text] [Related]
9. A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.
Zelek L; Debourdeau P; Bourgeois H; Wagner JP; Brocard F; Lefeuvre-Plesse C; Chauffert B; Leheurteur M; Bachet JB; Simon H; Mayeur D; Scotté F
Oncologist; 2021 Oct; 26(10):e1870-e1879. PubMed ID: 34216177
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study.
Chang J; Chen G; Wang D; Wang G; Lu S; Feng J; Li W; Li P; Lanzarotti C; Chessari S; Zhang L
Cancer Med; 2020 Jul; 9(14):5134-5142. PubMed ID: 32472742
[TBL] [Abstract][Full Text] [Related]
11. Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies.
Schwartzberg L; Karthaus M; Rossi G; Rizzi G; Borroni ME; Rugo HS; Jordan K; Hansen V
Cancer Med; 2019 May; 8(5):2064-2073. PubMed ID: 30968588
[TBL] [Abstract][Full Text] [Related]
12. Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data.
Natale JJ; Spinelli T; Calcagnile S; Lanzarotti C; Rossi G; Cox D; Kashef K
J Oncol Pharm Pract; 2016 Jun; 22(3):485-95. PubMed ID: 25998320
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.
Kurteva G; Chilingirova N; Rizzi G; Caccia T; Stella V; Bernareggi A
Eur J Pharm Sci; 2019 Nov; 139():105041. PubMed ID: 31404621
[TBL] [Abstract][Full Text] [Related]
14. Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV).
Navari RM
Drug Des Devel Ther; 2015; 9():155-61. PubMed ID: 25552904
[TBL] [Abstract][Full Text] [Related]
15. Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting.
Keating GM
Drugs; 2015 Dec; 75(18):2131-41. PubMed ID: 26613606
[TBL] [Abstract][Full Text] [Related]
16. Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens.
Jordan K; Gralla R; Rizzi G; Kashef K
Support Care Cancer; 2016 Nov; 24(11):4617-25. PubMed ID: 27334131
[TBL] [Abstract][Full Text] [Related]
17. Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Zelek L; Navari R; Aapro M; Scotté F
Cancer Med; 2023 Aug; 12(15):15769-15776. PubMed ID: 37537943
[TBL] [Abstract][Full Text] [Related]
18. Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.
Lorusso V; Karthaus M; Aapro M
Future Oncol; 2015; 11(4):565-77. PubMed ID: 25360998
[TBL] [Abstract][Full Text] [Related]
19. Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
Aapro M; Hesketh PJ; Jordan K; Gralla RJ; Rossi G; Rizzi G; Palmas M
Oncologist; 2016 Apr; 21(4):494-502. PubMed ID: 27000465
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patients.
Aapro M; Jordan K; Gralla RJ; Rizzi G; Rossi G; Palmas M; Alyasova AV; Lisyanskaya AS; Bošnjak SM; Hesketh PJ
J Geriatr Oncol; 2017 Jan; 8(1):56-63. PubMed ID: 27889278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
